[
  {
    "ts": null,
    "headline": "Elevance Health Inc. stock outperforms competitors on strong trading day",
    "summary": "Elevance Health Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3ee11f9c35233110ebb30a345cea5429fa0e57ad5351ae425e4c9bbf877cb802",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754671500,
      "headline": "Elevance Health Inc. stock outperforms competitors on strong trading day",
      "id": 136301497,
      "image": "",
      "related": "ELV",
      "source": "MarketWatch",
      "summary": "Elevance Health Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3ee11f9c35233110ebb30a345cea5429fa0e57ad5351ae425e4c9bbf877cb802"
    }
  },
  {
    "ts": null,
    "headline": "3 SWANs On Sale",
    "summary": "BMY, REXR, and ELV offer a 4.2% yield, strong credit ratings, and deep value with long-term upside potential. See why these dividend stocks are worth a look.",
    "url": "https://finnhub.io/api/news?id=1b619d88d95c91cfc8b440986f75fc461371d93c00fdc10f11e666e7ceeaeb08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754636400,
      "headline": "3 SWANs On Sale",
      "id": 136265582,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150801098/image_2150801098.jpg?io=getty-c-w1536",
      "related": "ELV",
      "source": "SeekingAlpha",
      "summary": "BMY, REXR, and ELV offer a 4.2% yield, strong credit ratings, and deep value with long-term upside potential. See why these dividend stocks are worth a look.",
      "url": "https://finnhub.io/api/news?id=1b619d88d95c91cfc8b440986f75fc461371d93c00fdc10f11e666e7ceeaeb08"
    }
  },
  {
    "ts": null,
    "headline": "Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral",
    "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On July 25, Baird analyst Michael Ha reduced the price target on the company’s stock to $297 from $492, while keeping a “Neutral” rating, as reported by The Fly. This comes as part of an update on the managed […]",
    "url": "https://finnhub.io/api/news?id=8d92f0dbe59880d1a7c25059baff79d7fc82e0e3b3efadfad40a75bc9b69a89c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754624907,
      "headline": "Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral",
      "id": 136267328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On July 25, Baird analyst Michael Ha reduced the price target on the company’s stock to $297 from $492, while keeping a “Neutral” rating, as reported by The Fly. This comes as part of an update on the managed […]",
      "url": "https://finnhub.io/api/news?id=8d92f0dbe59880d1a7c25059baff79d7fc82e0e3b3efadfad40a75bc9b69a89c"
    }
  },
  {
    "ts": null,
    "headline": "UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects",
    "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a ‘Buy’ rating on the stock and a $435 price target. The positive stance follows the healthcare company’s second-quarter results. The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. […]",
    "url": "https://finnhub.io/api/news?id=4d77289553bf5c1e029e58041d7a67bc8b5781c369f7eacab04fa553d18cac5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754624877,
      "headline": "UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects",
      "id": 136267329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a ‘Buy’ rating on the stock and a $435 price target. The positive stance follows the healthcare company’s second-quarter results. The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. […]",
      "url": "https://finnhub.io/api/news?id=4d77289553bf5c1e029e58041d7a67bc8b5781c369f7eacab04fa553d18cac5c"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Health Insurers See Costs Mount, Income Estimates Decline In Q2",
    "summary": "Many of the largest publicly traded US health insurers had a difficult second quarter as rising costs associated with government-subsidized health plans exacerbated ongoing declines in EPS.",
    "url": "https://finnhub.io/api/news?id=465563402fabdca904849453a77e383db2b22b84a3fdc04ee6fab775bfbf5f65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754623500,
      "headline": "U.S. Health Insurers See Costs Mount, Income Estimates Decline In Q2",
      "id": 136264838,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1094776474/image_1094776474.jpg?io=getty-c-w1536",
      "related": "ELV",
      "source": "SeekingAlpha",
      "summary": "Many of the largest publicly traded US health insurers had a difficult second quarter as rising costs associated with government-subsidized health plans exacerbated ongoing declines in EPS.",
      "url": "https://finnhub.io/api/news?id=465563402fabdca904849453a77e383db2b22b84a3fdc04ee6fab775bfbf5f65"
    }
  }
]